COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Luteal Phase Support in Insemination Cycles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03115307
Recruitment Status : Completed
First Posted : April 14, 2017
Last Update Posted : January 27, 2020
Information provided by (Responsible Party):
Tampere University Hospital

Brief Summary:
This study is a prospective randomized trial with 242 IUI cycles. Patients are randomized in two groups including 121 cycles in each group. A total of 255 cycles in 167 patients are finally recruited. In the first group, the patients will be treated with triptorelin (Gonapeptyl®) in their luteal phase. As for the other group, the patients will undergo the luteal phase without any supportive medication. This study is going to clarify the role of the gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter. The benefit of the treatment is measured by the numbers in the live birth and clinical pregnancy rates.

Condition or disease Intervention/treatment Phase
Infertility, Female Drug: Triptorelin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 167 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Protocol for a Randomized, Controlled Study to Compare the Use of Gonodotropin-releasing Hormone Agonist Triptoreline (Gonapeptyl®) for Luteal Phase Support Versus Natural Luteal Phase in the Insemination Cycles
Actual Study Start Date : January 2017
Actual Primary Completion Date : November 2019
Actual Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Gonapeptyl
In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
Drug: Triptorelin
Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.

No Intervention: Control group
In the control group, there are no luteal phase medications in the insemination cycle.

Primary Outcome Measures :
  1. Live birth rate [ Time Frame: At possible delivery (about 40 weeks) ]

Secondary Outcome Measures :
  1. Ongoing pregnancy rate [ Time Frame: After two weeks ]
  2. Miscarriage rate [ Time Frame: During subsequent about 40 weeks of pregnancy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 43 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • - Patients with ovarian stimulation cycles preparing to insemination
  • Patients with medical ovarian stimulation protocols including GnRH agonist, aromatase inhibitors and different combinations of GnRH agonists and aromatase inhibitors are included
  • Patient's willingness to participate in the study

Exclusion Criteria:

  • - Failure in the ovarian stimulation cycle
  • Failures in executing the insemination
  • Failures in giving the sperm sample
  • Major troubles in sperm parameters leading to an inadequate sample to accomplish intrauterine insemination
  • Patients with primarily planned progesterone luteal support

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03115307

Layout table for location information
Tampere University Hospital
Tampere, Finland
Sponsors and Collaborators
Tampere University Hospital
Layout table for investigator information
Principal Investigator: Helena Tinkanen Tampere University Hospital
Layout table for additonal information
Responsible Party: Tampere University Hospital Identifier: NCT03115307    
Other Study ID Numbers: R16171M
2016-002321-11 ( EudraCT Number )
First Posted: April 14, 2017    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tampere University Hospital:
Luteal phase support
Gonadotropin-releasing hormone agonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Infertility, Female
Genital Diseases, Male
Genital Diseases, Female
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents